Monthly Archive: April, 2016

How is innovative neurology research energising myasthenia?

Myasthenia gravis (MG) is one of the best characterised neurological disorders. The hallmark of MG is fatigable weakness. This manifests as intermittent ptosis (droopy eyelids), diplopia (double vision), and limb weakness. There are two main types-ocular… Continue reading

Will a pill really hold the cure for CMT?

Charcot Marie Tooth disease (CMT) is the most important inherited peripheral neuropathy. As with most genetic diseases, there is no cure for CMT. The best neurologists can offer at the moment is supportive treatment for complications of… Continue reading

What’s happening at the cutting edge of MSA?

Multiple system atrophy (MSA) is a mimic of Parkinson’s disease (PD). Neurologists suspect MSA in people with apparent PD who, in addition, have other defining features. In many people with MSA their prominent symptoms are cerebellar dysfunction… Continue reading

What is the state of Parkinson’s disease biomarkers?

Neurologists are always cautious when making a diagnosis of Parkinson’s disease (PD). This shouldn’t be the case because PD is not difficult to recognise-at least not most of the time. For one, PD has classical clinical signs-… Continue reading

What precisely is the driver for essential tremor?

Neurologists do not break into a sweat when they make the diagnosis of essential tremor (ET). Theoretically, at least, they shouldn’t. Essential tremor presents with an obvious shaking of the hands when performing tasks; this is… Continue reading

How is neurology stamping out the anguish of Duchenne?

Duchenne muscular dystrophy (DMD) is the most familiar of the inherited muscle diseases called muscular dystrophies. DMD is life limiting, but advances in care are enabling children born with this disease to survive… Continue reading